The guidance addresses questions that manufacturers, packers, distributors, and their representatives (firms) may have when developing FDA-regulated promotional labeling and advertisements for prescription reference products, biosimilar products, and interchangeable biosimilar products.
Similar Posts
Caspofungin Injection
Caspofungin InjectionSabores Bakery, Dba Sabores A Tu Mesa, Issues Allergy Alert on Undeclared Milk in Mousse Desserts
Sabores Fit Bakery of Kissimmee, FL is recalling MOUSSE DESSERTS, because they may contain undeclared Milk, Eggs, Soy Ingredients (Soybean oil, Soy Lecithin), Wheat, Tree Nuts ( Almonds, Hazelnuts ). People who have an allergy or severe sensitivity to these allergens run the risk of serioAspirin for Reducing Your Risk of Heart Attack and Stroke: Know the Facts
Information on using aspirin daily, over-the-counter, with other medicines, as well as its side effectsBRS Analytical Services, LLC – 711133 – 09/17/2025
CGMP/Finished Pharmaceuticals/AdulteratedUntitled Letters
These letters are supplied by the CDER Freedom of Information Office and only cover Office of Prescription Drug Promotion’s untitled letters. FDA may have redacted or edited some of the letters to remove confidential information.Clinical Decision Support Software
This guidance clarifies the scope of FDA’s oversight of clinical decision support software intended for health care professionals (HCPs) as devices.